Udayavni Special

Gold nanoparticles used to treat prostate cancer for the first time


Team Udayavani, Nov 9, 2018, 5:14 PM IST

Washington: Scientists are using gold nanoparticles that act as tumour-seeking missiles to target prostate cancer, in a first-of-its-kind clinical trial.

The nanoparticles or nanoshells, are made of small layers of silica glass formed into a sphere and wrapped in a thin layer of gold.

The shells seek out and saturate cancerous cells, and their advanced vibrational properties are then harnessed to cause the tumourous tissue to pulse with extreme temperature when light is applied through a laser specifically designed to excite the particles.

The oscillation kills the cancer cells while preserving the healthy tissue, avoiding the nerves and urinary sphincter. This procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.

“This therapy could be life-changing for men diagnosed with prostate cancer and I am honoured to be among the first doctors the US Food and Drug Administration approved to put it to the test,” said Steven Canfield from The University of Texas in the US.

Prostate cancer begins when cells in a man’s prostate gland mutate and start to grow uncontrollably.

Treatment options have traditionally included radical prostatectomy, which is the removal of the prostate gland and some of the tissue around it, radiation therapy and cryotherapy, among others. These methods carry the potential to have a negative impact on urinary function and sexual performance.

“The side effects of current prostate cancer treatments can be extremely traumatic. This new technology holds the potential to eliminate those life-altering effects, while still removing the cancer tissue and reducing hospital and recovery time,” Canfield said.

“In fact, the first patient in the trial was actually riding a bike within a week of his treatment,” he said.

The gold nanoparticles were invented by Naomi Halas, the head of Rice University in the US.

Canfield worked closely with Halas and Nanospectra Biosciences, the company where the shells are licensed, to incorporate the state-of-the-art technology into the trial that is also underway at the Icahn School of Medicine at Mount Sinai and the University of Michigan to test the efficacy of the therapy.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Why are you so scared of saffron: Raghupathi Bhat questions Siddaramaiah

Guj: 2 killed in fire in Surat packaging unit; over 70 rescued

State govt lifts curbs at MM Hills pilgrimage centre

Udupi: Children get Covid shots only if adults are vaccinated

Twin peaks: Sensex crosses 61,800, Nifty at record 18,460

A model govt. school for every gram panchayat on cards

Army chopper crash: Co-pilot’s body found after two months from dam in Jammu and Kashmir

Related Articles More

People want to use bleach and antiseptic for COVID and are calling us for advice

Long Covid may not be as fatal as acute COVID-19 but can worsen existing ailments, say experts

How many lives have coronavirus vaccines saved? We used state data on deaths and vaccination rates to find out

COVID and flu: how big could the dual threat be this winter?

Teen mental health during the COVID-19 pandemic

MUST WATCH

Raw Banana Flour | BAKAHU Shavige Preparation

Gowli Traditional Dance Performence at Dandeli

Mysore Dasara 2021 : Farewell to Dasara Elephants

Benefits of paddy farming

UDAYAVANI NEWS BULLETIN|17/10/2021


Latest Additions

Delhi Woman’s initiative on metro aims to provide everyone with the opportunity to read.

Farmers block train traffic in Punjab as part of ‘rail roko’ stir over Lakhimpur incident

Pooja Bedi tests positive for COVID-19, says staying unvaccinated her ‘personal decision’

Rupee trades almost flat at 75.28 against USD in opening deals

Why are you so scared of saffron: Raghupathi Bhat questions Siddaramaiah

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.